bevacizumab + fluorouracil + irinotecan

This is a combination regimen consisting of three drugs: - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) which tumors need to grow. - **Fluorouracil** (5-FU) is an antimetabolite chemotherapy agent that interferes with DNA synthesis by inhibiting thymidylate synthase, leading to cell death in rapidly dividing cells. - **Irinotecan** is a topoisomerase I inhibitor that prevents DNA from unwinding and duplicating, resulting in cancer cell death. This combination is most commonly used as part of the "FOLFIRI" regimen (which also includes leucovorin/folinic acid) plus bevacizumab for the treatment of metastatic colorectal cancer. The addition of bevacizumab to FOLFIRI has been shown to improve progression-free and overall survival compared to chemotherapy alone. Each component targets cancer through different mechanisms—bevacizumab blocks tumor blood supply, while fluorouracil and irinotecan directly kill tumor cells[1][6][7].

Other names

FOLFIRI + bevacizumabFOLFIRI-BEVACIZUMABbevacizumab-fluorouracil-irinotecan